DGX vs UNH vs CVS vs VEEV vs ELV

For growth investors, Veeva Systems Inc.

(VEEV) is the stronger pick with 16. 3% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). Elevance Health Inc. (ELV) offers the better valuation at 14. 8x trailing P/E (13. 9x forward), making it the more compelling value choice. Analysts rate UnitedHealth Group Incorporated (UNH) a "Buy" — based on 52 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Elevance Health Inc.

(ELV) is the cheapest at 14. 8x versus CVS Health Corporation at 62. 8x. On forward P/E, CVS Health Corporation is actually cheaper at 12. 2x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Veeva Systems Inc. wins at 1. 04x versus Elevance Health Inc. 's 2. 01x — a reasonable growth-adjusted valuation.

Over the past 5 years, Quest Diagnostics Incorporated (DGX) delivered a total return of +47.

7%, compared to -35. 3% for Veeva Systems Inc. (VEEV). Over 10 years, the gap is even starker: VEEV returned +519. 4% versus CVS's +3. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.

05β versus Veeva Systems Inc. 's 0. 77β — meaning VEEV is approximately 1430% more volatile than CVS relative to the S&P 500. On balance sheet safety, Veeva Systems Inc. (VEEV) carries a lower debt/equity ratio of 1% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Veeva Systems Inc.

(VEEV) is pulling ahead at 16. 3% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Veeva Systems Inc. grew EPS 25. 9% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, VEEV leads at 14. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Veeva Systems Inc.

(VEEV) is the more profitable company, earning 28. 4% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 28. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VEEV leads at 28. 7% versus 2. 6% for CVS. At the gross margin level — before operating expenses — VEEV leads at 75. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Veeva Systems Inc. (VEEV) is the more undervalued stock at a PEG of 1. 04x versus Elevance Health Inc. 's 2. 01x. A PEG below 1. 5 suggests fair-to-attractive pricing relative to expected growth. On forward earnings alone, CVS Health Corporation (CVS) trades at 12. 2x forward P/E versus 20. 2x for UnitedHealth Group Incorporated — 8. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for VEEV: 66. 5% to $280. 10.

In this comparison, CVS (3.

1% yield), UNH (2. 4% yield), ELV (1. 8% yield), DGX (1. 6% yield) pay a dividend. VEEV does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Quest Diagnostics Incorporated (DGX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

07), 1. 6% yield, +181. 3% 10Y return). Both have compounded well over 10 years (DGX: +181. 3%, VEEV: +519. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: DGX is a mid-cap quality compounder stock; UNH is a large-cap quality compounder stock; CVS is a mid-cap income-oriented stock; VEEV is a mid-cap high-growth stock; ELV is a mid-cap deep-value stock. DGX, UNH, CVS, ELV pay a dividend while VEEV does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.